NDAINTRAVENOUSPOWDERPriority Review
Approved
Oct 2015
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Clinical Trials
20
Data completeness
6/8 — Strong
Priority Review
YONDELIS (trabectedin) by Johnson & Johnson is alkylating activity [moa]. Approved for alkylating drug [epc]. First approved in 2015.
Drug data last refreshed 11h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
YONDELIS (trabectedin) is an intravenous alkylating small-molecule chemotherapy approved in 2015 for select cancers. It works by binding to DNA and disrupting cellular function through alkylating activity. The drug is administered as an IV powder infusion.
$0.578MPart D
LOE ApproachingDeclining
1.8 years to LOELimited commercial opportunity with LOE approaching in 1.8 years; small team focus on maintaining existing patient base rather than growth.
Mechanism of Action
Alkylating Activity
Pharmacologic Class:
Alkylating Drug
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Prospective Study to Evaluate Patient Reported Outcomes (PRO) During Rechallenge With Trabectedin in Sarcoma Patients
Started Oct 2023
7 enrolled
Soft Tissue Sarcoma
Study on Trabectedin in Advanced Rearranged Mesenchymal Chondrosarcoma
Started Sep 2021
16 enrolled
Mesenchymal Chondrosarcoma
Treatment of Milademetan Versus Trabectedin in Patient With Dedifferentiated Liposarcoma
Started Jul 2021
175 enrolled
Dedifferentiated Liposarcoma
SARC037: A Phase I/II Study to Evaluate the Safety of Trabectedin in Combination With Irinotecan in Ewing Sarcoma Patients
Started Jan 2021
37 enrolled
Ewing Sarcoma
Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma
Started Mar 2020
29 enrolled
SarcomaSarcoma Metastatic
Worked on YONDELIS at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.